Related Experiment Video
Updated: Apr 11, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.5K
Doxycycline-induced hypoglycaemia
C H Tan1, C Shelley1, K E Harman1
1Department of Dermatology, Leicester Royal Infirmary, Infirmary Square, Leicester, UK.
Clinical and Experimental Dermatology
|June 9, 2015
Summary
Doxycycline, a common antibiotic, can cause serious adverse reactions like hypoglycemia, even in patients without diabetes. This rare side effect highlights the need for careful monitoring during tetracycline treatment.
Area of Science:
- Pharmacology
- Endocrinology
- Internal Medicine
Background:
- Tetracyclines, including doxycycline, are frequently prescribed antibiotics.
- Serious adverse reactions (SARs) to tetracyclines are uncommon.
- Hypoglycemia is not a recognized complication of tetracycline therapy.
Observation:
- An 80-year-old male patient with insulin-dependent diabetes was enrolled in a research study.
- The patient developed unexpected hypoglycemia during doxycycline treatment.
- This event represents a potential serious adverse reaction.
Findings:
- Doxycycline treatment was associated with a serious adverse reaction of hypoglycemia.
- The occurrence of hypoglycemia during tetracycline use is rare and not well-documented.
- This case suggests a potential link between doxycycline and hypoglycemia.
Implications:
- Clinicians should be aware of the potential for doxycycline-induced hypoglycemia, especially in vulnerable patients.
- Further research is needed to determine the frequency and mechanisms of this rare adverse reaction.
- Enhanced vigilance and monitoring may be necessary for patients on tetracycline therapy.
More Related Videos
10:49Doxycycline Loaded Collagen-Chitosan Composite Scaffold for the Accelerated Healing of Diabetic Wounds
Published on: August 21, 2021
5.1K
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
72.7K
Related Concept Videos
01:15Hypoglycemia and Glucagon
1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
01:06Oral Hypoglycemic Agents: Glinides
981
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
981
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
980
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
980
01:17Oral Hypoglycemic Agents: Sulfonylureas
1.7K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.7K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
901
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
901
01:16Insulin: Dosing Regimen and Adverse Effects
1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K